Novo Nordisk (NYSE:NVO) announced that users of the Abbott (NYSE:ABT) FreeStyle LibreLink app can connect to its smart insulin pens.
People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. Users of the Abbott FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology can see a range of information related to their diabetes. This includes dose timing and the amount of insulin taken, plus how those metrics impact their individual glucose patterns.
Get the full story at our sister site, Drug Delivery Business News.